A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0)

Clinical Trial ID NCT00626548

Rank	Title	Journal	Year	PubWeight™‹?›
1	G protein-coupled receptors: novel targets for drug discovery in cancer.	Nat Rev Drug Discov	2011	3.31
2	Bone metastasis in prostate cancer: emerging therapeutic strategies.	Nat Rev Clin Oncol	2011	2.20
3	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.	J Urol	2012	1.61
4	Castration-resistant prostate cancer: mechanisms, targets, and treatment.	Prostate Cancer	2012	1.47
5	Emerging therapies to prevent skeletal morbidity in men with prostate cancer.	J Clin Oncol	2011	1.31
6	Emerging novel therapies in the treatment of castrate-resistant prostate cancer.	Can Urol Assoc J	2011	1.04
7	Update on options for treatment of metastatic castration-resistant prostate cancer.	Onco Targets Ther	2010	1.00
8	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.	Int J Mol Sci	2013	0.88
9	Emerging targeted therapies for castration-resistant prostate cancer.	Front Endocrinol (Lausanne)	2012	0.81
10	Research in castration-resistant prostate cancer: what does the future hold?	Curr Oncol	2010	0.79